Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.
Diffuse Large B-cell Lymphoma|Acute Lymphoblastic Leukemia (ALL)
Number of medicine, surgery, obstetrics and odontology (MCO) stays per patient, Up to 36 months|Number of outpatient visit (ACE) stays per patient, Up to 36 months|Number of emergency room visits not followed by hospitalisation per patient, Up to 36 months|Number of aftercare and rehabilitation (SSR) stays per patient, Up to 36 months|Number of homecare (HAD) stays per patient, Up to 36 months|Number of consultations per type of healthcare professional, Up to 36 months|Number of consultations per patient (all consultations combined), Up to 36 months|Number of patients who died, Up to 36 months|Cost of MCO hospitalisation, Up to 36 months|Cost of CAR-T on the supplementary list, Up to 36 months|Cost of medicines on the supplementary list (excluding CAR-T), Up to 36 months|Hospitalisation cost, Up to 36 months
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.